Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 11/20 | 0.67 |
| ▸ | THRB | P10828 | 11/20 | 0.67 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.67 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | ASPH | Q12797 | 1/20 | 0.67 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22441916 | 0.99 | THRA (0.66) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Sulfuric Acid SCHEMBL22441927 | 0.96 | THRA (0.62) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL31296198 | 0.92 | EGLN1 (0.64) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL28624477 | 0.92 | EGLN1 (0.64) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL31296196 | 0.91 | EGLN1 (0.62) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL523175 | 0.91 | EGLN1 (0.62) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL28488469 | 0.90 | EGLN1 (0.64) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL22958815 | 0.89 | EGLN1 (0.56) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL22441931 | 0.89 | THRA (0.56) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL22441911 | 0.88 | THRA (0.65) | THRATHRBEGLN1BBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300073-B | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-119320350-A | Preparation method of roflumilast intermediate | 浙江工业大学 | 2025-01-17 | — | — | CN | disclosed |
| WO-2025001086-A1 | SYNTHESIS METHOD FOR ROXADUSTAT INTERMEDIATE | 江苏海洋大学 | 2025-01-02 | — | — | WO | disclosed |
| CN-113754569-B | Intermediate compound and preparation method and application thereof | 四川国为制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117946003-A | Roflumilast intermediate and preparation method thereof | 成都倍特药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-116803986-B | Synthesis method of roflumilast intermediate | 江苏海洋大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-112300073-B | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3717456-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | Dr. Reddy's Laboratories Limited (IN) | 2020-10-07 | — | — | EP | disclosed |
| US-20200299242-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-09-24 | — | — | US | disclosed |
| US-20200299242-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-09-24 | — | — | US | disclosed |
| US-20200299242-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-09-24 | — | — | US | disclosed |
| CN-111592490-A | Preparation method of key intermediate of roxasistat | 浙江工业大学 | 2020-08-28 | — | — | CN | disclosed |
| CN-111566090-A | Preparation method of roxasistat and intermediate thereof | 雷迪博士实验室有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-111566090-A | Preparation method of roxasistat and intermediate thereof | 雷迪博士实验室有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-3305769-B1 | METHOD FOR PREPARATION OF (7-PHENOXY-4-HYDROXY-1-METHYL-ISOQUINOLINE-3-CARBONYL)-GLYCINE (ROXEDUSTAT) AND ITS INTERMEDIATES BASED ON SIMULTANEOUS OPENING OF OXAZOLIC RING, FISSION OF ETHER AND CREATION OF IMINE | ZENTIVA KS (CZ) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019106621-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-06-06 | — | — | WO | disclosed |
| EP-3305769-A1 | METHOD FOR PREPARATION OF (7-PHENOXY-4-HYDROXY-1-METHYL-ISOQUINOLINE-3-CARBONYL)-GLYCINE (ROXEDUSTAT) AND ITS INTERMEDIATES BASED ON SIMULTANEOUS OPENING OF OXAZOLIC RING, FISSION OF ETHER AND CREATION OF IMINE | Zentiva K.S. (CZ) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299242-A1 | PROCESS FOR THE PREPARATION OF ROXADUSTAT AND ITS INTERMEDIATES | CYP3A7, CYP3A4, CYP3A5 | THRA 4004/4885THRB 4557/4885EGLN1 86/4885 |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | SRM, SMS, SMOX | THRA 3024/4885THRB 4259/4885EGLN1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.